Hamdy Marwa, Kassim Samar Kamal, Khairy Eman, Maher Mohsen, Mansour Khaled Amr, Albreedy Ashraf M
Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo, Egypt, P.O. box 11381.
Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo, Egypt, P.O. box 11381.
Gene. 2018 Apr 5;649:74-79. doi: 10.1016/j.gene.2018.01.077. Epub 2018 Jan 31.
Ghrelin (GHRL) has important implications for liver disease. It has anti-inflammatory effects, regulates cell proliferation, modulates the fibrogenic response and protects liver tissue. Genetic variations in the GHRL gene may play a crucial role in the development of chronic hepatitis (CH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Therefore, we examined the association of GHRL gene polymorphisms (rs26312 and rs27647), and its serum level to virologic responses to combined sofosbuvir and Simeprevir therapy for a course of 12 successive weeks in Egyptian chronic hepatitis C (CHC) patients.
Human genomic and clinical data were collected from 100 Egyptian participants in this study, 90 HCV patients who received sofosbuvir and Simeprevir and 10 non-HCV healthy subjects. Genotyping of GHRL rs26312 and rs27647, were determined with the TaqMan qRT-PCR allele detection assay. The serum GHRL concentrations were determined using enzyme-linked immunosorbent assay (ELISA).
GHRL polymorphisms (rs26312 and rs27647) genotype distributions and allele frequencies did not differ between HCV patients and normal healthy subjects or between patient groups when compared according to the therapeutic response. In addition, we found significant lower serum GHRL levels in CHC patients compared with the healthy controls. However, there was no significant association of the GHRL rs26312 and rs27647 polymorphisms with GHRL levels in CHC patients. We conclude that GHRL SNPs (rs26312 and rs27647) do not affect response to combined sofosbuvir and Simeprevir treatment in chronic Egyptian HCV patients.
胃饥饿素（GHRL）对肝脏疾病具有重要影响。它具有抗炎作用，调节细胞增殖，调节纤维化反应并保护肝组织。GHRL基因的遗传变异可能在慢性肝炎（CH）、肝硬化（LC）和肝细胞癌（HCC）的发展中起关键作用。因此，我们研究了GHRL基因多态性（rs26312和rs27647）及其血清水平与埃及慢性丙型肝炎（CHC）患者连续12周联合使用索磷布韦和西米普明治疗的病毒学反应之间的关联。
本研究从100名埃及参与者中收集了人类基因组和临床数据，其中90名接受索磷布韦和西米普明治疗的HCV患者以及10名非HCV健康受试者。使用TaqMan qRT-PCR等位基因检测法测定GHRL rs26312和rs27647的基因分型。使用酶联免疫吸附测定（ELISA）测定血清GHRL浓度。
根据治疗反应进行比较时，HCV患者与正常健康受试者之间或患者组之间的GHRL多态性（rs26312和rs27647）基因型分布和等位基因频率没有差异。此外，我们发现CHC患者的血清GHRL水平明显低于健康对照组。然而，CHC患者中GHRL rs26312和rs27647多态性与GHRL水平之间没有显著关联。我们得出结论，GHRL单核苷酸多态性（rs26312和rs27647）不影响埃及慢性HCV患者对索磷布韦和西米普明联合治疗的反应。
